ANI Pharmaceuticals, Inc. (ANIP) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

SA Transcripts158.92K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call ANI Pharmaceuticals, Inc. (ANIP) Barclays 28th Annual Global Healthcare Conference March 11, 2026 3:00 PM EDT Company Participants Nikhil Lalwani - President, CEO & DirectorStephen Carey - Senior VP of Finance & CFO Conference Call Participants Glen Santangelo - Barclays Bank PLC, Research Division Presentation Glen SantangeloBarclays Bank PLC, Research Division Okay. Good afternoon, everyone. Thank you for joining us. For our next presentation, we're excited to have ANI Pharmaceuticals here with us. Representing the company to my right is Nikhil Lalwani, who's the President and Chief Executive Officer of the company; and to his right, Stephen Carey is the Chief Financial Officer of the company. For those of you who don't know me, I'll just quickly introduce myself. My name is Glen Santangelo. I'm the analyst at Barclays responsible for the specialty pharmaceuticals sector, among a few other things. But again, we're very happy to have you here, Nikhil and Stephen. So thank you guys very much for taking the time out of your schedules. Nikhil LalwaniPresident, CEO & Director Thank you, Glen, and thank you for having me. Question-and-Answer Session Glen SantangeloBarclays Bank PLC, Research Division Okay. Excellent. So why don't we just sort of dive right into it? I mean, 2025 was just a great year for the company. And I finally think that we can sort of reposition you no longer as a generics company that has rare disease assets. We're now going to call you a rare disease company that also happens to have a generics business as you cross that 50% threshold. So congratulations on that milestone. Maybe a good place to start is if you just want to sort of level set everybody and talk about 2025 and the momentum you had sort of into the end of the year